¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimum inhibitory dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
  • inhibitory interneuron
    ¾ïÁ¦»çÀ̽Ű漼Æ÷, ¾ïÁ¦°³Àç´º·±
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÀÌÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÀÌÈÄÀüÀ§
  • inhibitory synapse
    ¾ïÁ¦½Ã³À½º, ¾ïÁ¦¿¬Á¢
  • inhibitory transmitter
    ¾ïÁ¦Àü´Þ¹°Áú
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    Ȳ(»ö)üÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ, ´ë½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • peripheral inhibitory field
    ¸»ÃʾïÁ¦¿µ¿ª
  • reticular inhibitory area
    ±×¹°Ã¼¾ïÁ¦ºÎÀ§
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • therapeutic dose
    Ä¡·á¿ë·®, Ä¡·á¼±·®
  • high-dose
    °í¿ë·®
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory effect
    ¾ïÁ¦È¿°ú
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    ȲüÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • peripheral inhibitory field
    ¸»ÃʾïÁ¦¿µ¿ª
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • hypothalamic inhibitory hormone
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
  • inhibitory interneuron
    ¾ïÁ¦»çÀ̽Ű漼Æ÷
  • inhibitory synapse
    ¾ïÁ¦¿¬Á¢
  • inhibitory transmitter
    ¾ïÁ¦Àü´Þ¹°
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÈÄÀüÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
  • inhibitory nerve
    ¾ïÁ¦½Å°æ(åäð¤ãêÌè).
  • inhibitory nerve
    ¾ïÁ¦½Å°æ.
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory synapse
    ¾ïÁ¦¼º(åäð¤àõ) ½Ã³³½º.
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º.
  • inhibitory transmitter
    ¾ïÁ¦¼º Àü´Þ¹°Áú.
  • inhibitory zone
    ¾ïÁ¦¹üÀ§(åäð¤ÛôêÌ).
  • prolactin-inhibitory factor(PIF)
    ÇÁ·Î¶ôƾ ºÐºñ ¾ïÁ¦ ÀÎÀÚ
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
  • ED 50=ÊÝeffective dose 50%
    50% À¯È¿·®.
  • ED=ÊÝeffective dose
    À¯È¿·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cumulative dose ; cumulate dose
    ´©Àû¿ë·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® , [¿¹¹æ] ÁýÀû¼±·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® .[¿¹¹æ]ÁýÀû¼±·®.
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • optimal dose ; optimum dose
    ¹æ»ç [¾à¸®,ÇØºÎ,¿¹¹æ]ÃÖÀû·®, ÀûÁ¤·®(ËøËøËâ).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • central inhibitory state
    ÁßÃß¾ïÁ¦»óÅÂ.
  • central inhibitory state
    ÁßÃß¼º ¾ïÁ¦»óÅÂ
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inhibitory autacoid
    ¾ïÁ¦¿À¿ÀŸÄÚÀ̵å.
  • inhibitory effect
    ¾ïÁ¦È¿°ú.
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inhibitory hormone
    ¾ïÁ¦(åäð¤)È£¸£¸ó.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • exposure dose
    ³ëÃâ·®(ÖÚõóÕá)
  • fractionated dose
    ºÐÇÒ·®(ÝÂùÜÕá)
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
  • lethal dose
    Ä¡»ç·®(öÈÞÝÕá)
  • maximum permissible dose
    ÃÖ´ëÇã¿ë·®(õÌÓÞúÉé»Õá)
  • median effective dose
    Á¤Áß À¯È¿·®(ïáñéêóüùÕá)
  • median hemolytic dose
    Á¤Áß ¿ëÇü·®(ïáñééÁúìÕá)
  • median immunizing dose
    Á¤Áß ¸é¿ª·®(ïáñéØóæµÕá)
  • median infectious dose
    Á¤Áß °¨¿°·®(ïáñéÊïæøÕá)
  • median lethal dose
    Á¤Áß Ä¡»ç·®(ïáñéöÈÞÝÕá)
  • median paralysis dose
    Á¤Áß ¸¶ºñ·®(ïáñ騫ÝöÕá)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • median toxic dose
    Á¤Áß µ¶¼º·®(ïáñéÔ¸àõÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • permissible dose
    Çã¿ë·®(úÉé»Õá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • permissible internal dose
    ³»ºÎÇã¿ë¼±·®
  • radiation absorbed dose
    ¶óµå, ¹æ»ç¼±Èí¼ö¼±·®
  • relative dose
    ºñ±³Á¶»ç·®, »ó´ëÁ¶»ç·®
  • single dose
    ÀÏȸ·®
  • skin dose
    ÇǺμ±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TD tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus...
MAD major affective disorder; mandibulo-acral dysplasia; maximum allowable dose; methylandrostenediol; m...
MLD manual lymph drainage; median lethal dose; metachromatic leukodystrophy; minimal lesion disease; min...
MIC Minimum(Minimal) Inhibitory Concentration
MAC MacConkey [broth]; major ambulatory category; malignancy-associated changes; maximum allowable conce...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MED minimum erythema dose
ID50 Inhibitory Dose
LogMAR Logarithm of the minimum angle of resolution
MBC Minimum Bactericidal Concentration
MDS Minimum Data Set
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • inhibitory afferent input
    ¾ïÁ¦¼º ±¸½É¼º ÀÔ·Â
  • inhibitory contribution
    ¾ïÁ¦¼º ºÐÆ÷
  • inhibitory hormone
    ¾ïÁ¦ È£¸£¸ó
    Ç¥Àû ±â°ü¿¡ ´ëÇÏ¿© ¾ïÁ¦ÀûÀ¸·Î ÀÛ¿ëÇϴ ȣ¸£¸ó.
  • inhibitory input
    ¿ªÁ¦¼º ÀÔ·Â
  • inhibitory interneuron
    ¾ïÁ¦ °³Àç ´º¿ì·±
  • inhibitory output cell
    ¾ïÁ¦ Ãâ·Â ¼¼Æ÷
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
    ¾ïÁ¦¼º ±¸½É·Î¿¡ ÀÏÁ¦È÷ Ãæµ¿ÀÌ °¡ÇØÁú ¶§ ½Ã³À½º ÈÄ ´º·Ð¿¡ ¹ßÇàÇÏ´Â ¸·ÀüÀ§ÀÇ Àϰú¼º °úºÐ±ØÀ̸ç, ÀÌ ¶§¹®¿¡ ½Å°æ ´ÜÀ§ÀÇ ¹ÝÀÀ¼ºÀÌ °¨¾àµÈ´Ù.
  • inhibitory substantia gelatinosa cell
    ¾ïÁ¦¼º ±³¾çÁú ¼¼Æ÷
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º
  • light touch inhibitory
    ºÒºû ÀÚ±Ø ¾ïÁ¦
  • macrophage migration inhibitory factor
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ, °Å½Ä ¼¼Æ÷ À¯ÁÖ ¾ïÁ¦ ÀÎÀÚ
  • migration inhibitory factor test
    À¯ÁÖ ÀúÁö ÀÎÀÚ ½ÃÇè
    ƯÀÌ Ç׿ø¿¡ ¹ÝÀÀÇÏ¿© ¸²ÇÁ±¸°¡ MIF¸¦ »ý¼ºÇÏ´Â µ¥ ´ëÇÑ »ýüÀÇ ½ÃÇè¹ýÀ¸·Î ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» Æò°¡ÇÏ´Â µ¥ »ç¿ëÇÑ´Ù. ÀϺΠ¸é¿ª °áÇÌ Áúº´, Áï DiGeorge ÁõÈıº, Wiskott-Aldrich ÁõÈıº, Hodgkin º´¿¡¼­´Â MIF°¡ »ý¼ºµÇÁö ¾Ê´Â´Ù.
  • peripheral inhibitory field
    ¸»ÃÊ ¾ïÁ¦¾ß
  • presynaptic inhibitory action
    ½Ã³³½ºÀü ¾ïÁ¦ ÀÛ¿ë
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º ¾ïÁ¦ ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
inhibitory junction potential Hyperpolarization of smooth muscle produced by stimulation of inhibitory nerves.
(05 Mar 2000)
inhibitory-motor <physiology> A term applied to certain nerve centers which govern or restrain subsidiary centers, from which motor impressions issue.
Source: Websters Dictionary
(01 Mar 1998)
inhibitory nerve <anatomy, nerve> A nerve conveying impulses that diminish functional activity in a part.
(05 Mar 2000)
inhibitory postsynaptic potential The change in potential produced in the membrane of the next neuron when an impulse which has an inhibitory influence arrives at the synapse; it is a local change in the direction of hyperpolarization; the frequency of discharge of a given neuron is determined by the extent to which impulses that lead to excitatory postsynaptic potential's predominate over those that cause inhibitory postsynaptic potential's.
(05 Mar 2000)
inhibitory synapse A synapse in which an action potential in the presynaptic cell reduces the probability of an action potential occurring in the postsynaptic cell. The most common inhibitory neurotransmitter is GABA, this opens channels in the postsynaptic cell which tend to stabilise its resting potential, thus rendering it less likely to fire.
See: excitatory synapse, presynaptic inhibition, postsynaptic inhibition.
(18 Nov 1997)
Leukaemia inhibitory factor <growth factor> Polypeptide growth factor or cytokine with wide range of activities. Regulates growth and differentiation of primordial germ cells and embryonic stem cells but has effects on peripheral neurons, osteoblasts, adipocytes and various cells of the myeloid lineage. Given to adult animals induces weight loss, behavioural disorders and bone abnormalities. Many of the effects of LIF in vitro can be mimicked by IL-6, oncostatin M and ciliary neurotrophic factor, all of which interact indirectly with gp130, a shared tranducer subunit.
(18 Nov 1997)
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
absorbed dose The amount of energy absorbed per unit mass of irradiated material at the target site; in radiation therapy, the former unit for absorbed dose is the rad; the current (S.I.) unit is the gray.
(05 Mar 2000)
air dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
bone marrow dose The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose.
(05 Mar 2000)
booster dose A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies.
(05 Mar 2000)
breast dose in mammography <radiology> 180 mrad / view -- mid-breast dose, guideline: less than 1 rad for 2-view exam
(12 Dec 1998)
maintenance dose In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
genetically significant dose <physics, radiobiology> The genetically significant dose is that which, if received by every member of the population, would be expected to produce the same genetic injury to the population as do the actual doses received by the individuals irradiated.
Thus, the genetically significant dose is the dose equivalent to the gonads weighted for the age and sex distribution in those members of the irradiated population expected to have offspring. The genetically significant dose is expressed in sieverts (or rem).
Acronym: GSD
(06 Aug 1998)
maximal dose <pharmacology> The largest amount of a drug or physical procedure that an adult can take with safety.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á